Royalty Pharma plc is a key player in the biopharmaceutical industry, specializing in the acquisition of biopharmaceutical royalties and funding innovation. With a focus on collaboration, the company works alongside academic institutions, research hospitals, and companies of various sizes to support the development of new therapies. Its diverse portfolio includes royalties on over 35 commercial products and 14 products in development, covering areas like rare diseases, cancer, and diabetes. Founded in 1996, Royalty Pharma is headquartered in New York, New York, marking its influence in the healthcare sector.
The tech stock selloff in July surprised the market but not those investors who were paying attention. As far back as April, Goldman Sachs (NYSE:GS | GS Price Prediction) warned of the…
With a market rotation underway, where should investors seeking opportunities in health care be looking? Analysts have high expectations for Alphatec.
Tuesday's additional top analyst upgrades and downgrades were on Adobe, AstraZeneca, Best Buy, Chemours, Oracle, Royalty Pharma, Teva Pharmaceutical and Tractor Supply.
Thursday's top analyst upgrades and downgrades included Alphabet, Allstate, Antero Midstream, Archer Daniels Midland, Capital One Financial, Chipotle Mexican Grill, Corning, Microsoft, PepsiCo, QuantumScape, Range Resources, Spotify Technology, Texas Instruments, Visa and…
Thursday’s additional top analyst upgrades and downgrades included Royalty Pharma, Twitter, UPS and more.
24/7 Wall St. has put together a preview of a few of the most anticipated quarterly reports due this week, including Disney, Cisco and McDonald's.
Practically any biotech company attempting almost anything COVID-19 related has seen massive gains. However, there is likely more to come for the rest of the year and into next year. These five…
Shares of these recently public companies still offer aggressive investors outstanding entry levels, but most have not seen their lockup periods end. They are rated Buy across Wall Street and also offer…
Royalty Pharma reported quarterly results on Wednesday morning that were boosted by Imbruvica and the addition of new royalties.
Chris Lange 24/7 Wall St. has put together a preview of Cisco Systems, Nio, Occidental Petroleum and some of the other most anticipated quarterly reports due this week.
24/7 has compiled a few biopharmaceutical names that have lagged the markets and recently have reported earnings. In a sense, the fundamentals have shown some light on these stocks, that they may…
